Pharsight

Drug Patents Expiring in 2035

1. Absorica Ld patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750711 SUN PHARM Low dose oral pharmaceutical composition of isotretinoin
May, 2035

(11 years from now)

US9700535 SUN PHARM Oral pharmaceutical composition of isotretinoin
Aug, 2035

(11 years from now)

Drugs and Companies using ISOTRETINOIN ingredient

Market Authorisation Date: 05 November, 2019

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

ABSORICA LD family patents

Family Patents

2. Accrufer patents expiration

ACCRUFER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9802973 SHIELD TX Crystalline forms of ferric maltol
Oct, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10179120 SHIELD TX Dosage regimen of ferric trimaltol
Jan, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 25, 2024

Drugs and Companies using FERRIC MALTOL ingredient

NCE-1 date: 2023-07-26

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage

ACCRUFER family patents

Family Patents

3. Adhansia Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500162 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10512612 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10292938 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US9974752 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10292939 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10512613 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10688060 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10449159 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10507186 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10568841 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10111839 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jun 28, 2024

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 February, 2019

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

ADHANSIA XR family patents

Family Patents

4. Adrenalin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130592 PAR STERILE PRODUCTS Epinephrine formulations
Mar, 2035

(11 years from now)

US9119876 PAR STERILE PRODUCTS Epinephrine formulations
Mar, 2035

(11 years from now)

US9295657 PAR STERILE PRODUCTS Epinephrine formulations
Mar, 2035

(11 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

How can I launch a generic of ADRENALIN before it's drug patent expiration?
More Information on Dosage

ADRENALIN family patents

Family Patents

5. Airduo Digihaler patents expiration

AIRDUO DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066957

(Pediatric)

TEVA PHARM Dry powder inhaler
Apr, 2035

(11 years from now)

US9415008

(Pediatric)

TEVA PHARM Dry powder inhaler
Apr, 2035

(11 years from now)

US9782551 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(11 years from now)

US9782550 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(11 years from now)

US10918816 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

6. Akynzeo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10676440 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(11 years from now)

US10961195 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(11 years from now)

US9951016 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(11 years from now)

US10233154 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(11 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 10 October, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

AKYNZEO family patents

Family Patents

7. Alecensa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350214 HOFFMANN-LA ROCHE Preparation containing tetracyclic compound at high dose
Apr, 2035

(11 years from now)

US11433076 HOFFMANN-LA ROCHE Preparation containing tetracyclic compound at high dose
Apr, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 6, 2024

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ALECENSA before it's drug patent expiration?
More Information on Dosage

ALECENSA family patents

Family Patents

8. Alunbrig patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10385078 TAKEDA PHARMS USA Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Nov, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 22, 2027
New Indication (I) May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage

ALUNBRIG family patents

Family Patents

9. Amvuttra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 13, 2027
Orphan Drug Exclusivity (ODE) Jun 13, 2029

Drugs and Companies using VUTRISIRAN ingredient

NCE-1 date: 2026-06-13

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

AMVUTTRA family patents

Family Patents

10. Aponvie patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11744800 HERON THERAPS INC Methods of use of emulsion formulations of an NK-1 receptor antagonist
Sep, 2035

(11 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(11 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(11 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(11 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 16 September, 2022

Treatment: A method for preventing of post-operative nausea and vomiting; A method of administering aprepitant for prevention of post-operative nausea and vomiting

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage

APONVIE family patents

Family Patents

11. Arakoda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11744828 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naïve subjects
Dec, 2035

(12 years from now)

US10342791 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Dec, 2035

(12 years from now)

US10888558 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Dec, 2035

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2023

Drugs and Companies using TAFENOQUINE SUCCINATE ingredient

NCE-1 date: 2022-07-20

Market Authorisation Date: 08 August, 2018

Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose

Dosage: TABLET;ORAL

More Information on Dosage

ARAKODA family patents

Family Patents

12. Arikayce Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10251900 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(11 years from now)

US10751355 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(11 years from now)

US9895385 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(11 years from now)

US11446318 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in non-cystic fibrosis adults as part o...

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

ARIKAYCE KIT family patents

Family Patents

13. Aristada patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10813928 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(11 years from now)

US9452131 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(11 years from now)

US10238651 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(11 years from now)

US11406632 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(11 years from now)

US9526726 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(11 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous injection

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA family patents

Family Patents

14. Aristada Initio Kit patents expiration

ARISTADA INITIO KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849894 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(11 years from now)

US11154552 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(11 years from now)

US10688091 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(11 years from now)

US10016415 ALKERMES INC Aripiprazole prodrug compositions
Sep, 2035

(11 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA INITIO KIT family patents

Family Patents

15. Armonair Digihaler patents expiration

ARMONAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782551 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(11 years from now)

US9782550 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(11 years from now)

US10918816 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

16. Axumin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933147 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(12 years from now)

US10716868 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(12 years from now)

US10124079 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(12 years from now)

US10967077 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(12 years from now)

Drugs and Companies using FLUCICLOVINE F-18 ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

AXUMIN family patents

Family Patents

17. Bafiertam patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566259 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(11 years from now)

US10098863 BANNER LIFE SCIENCES Fumarate esters
Feb, 2035

(11 years from now)

US9820961 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(11 years from now)

US10105336 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(11 years from now)

US9814691 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(11 years from now)

US9636318 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(11 years from now)

US9814692 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(11 years from now)

US10105335 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(11 years from now)

US9511043 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(11 years from now)

US9326965 BANNER LIFE SCIENCES Controlled release fumarate esters
Feb, 2035

(11 years from now)

US9517209 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(11 years from now)

US9820960 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(11 years from now)

US9326947 BANNER LIFE SCIENCES Controlled release fumarate esters
Feb, 2035

(11 years from now)

US10105337 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(11 years from now)

US9636319 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(11 years from now)

US10918616 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Jun, 2035

(11 years from now)

US10918617 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Aug, 2035

(11 years from now)

US10918615 BANNER LIFE SCIENCES Fumarate esters
Aug, 2035

(11 years from now)

US10945985 BANNER LIFE SCIENCES Fumarate ester dosage forms
Aug, 2035

(11 years from now)

Drugs and Companies using MONOMETHYL FUMARATE ingredient

Market Authorisation Date: 28 April, 2020

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

BAFIERTAM family patents

Family Patents

18. Balversa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9902714 JANSSEN BIOTECH Quinoxaline derivatives useful as FGFR kinase modulators
Mar, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 2023-04-13

Market Authorisation Date: 12 April, 2019

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage

BALVERSA family patents

Family Patents

19. Biktarvy patents expiration

BIKTARVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9708342 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
Jun, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10385067 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
Jun, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 7, 2023
Orphan Drug Exclusivity (ODE) Oct 7, 2028
M (M) Feb 24, 2024

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 2022-02-07

Market Authorisation Date: 07 February, 2018

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage

BIKTARVY family patents

Family Patents

20. Brexafemme patents expiration

BREXAFEMME's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10927142 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(11 years from now)

US10174074 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10370406 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 1, 2026
New Indication (I) Nov 30, 2025
Generating Antibiotic Incentives Now (GAIN) Jun 1, 2031

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

NCE-1 date: 2030-06-01

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)

Dosage: TABLET;ORAL

More Information on Dosage

BREXAFEMME family patents

Family Patents

21. Bunavail patents expiration

BUNAVAIL Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522188 BDSI Abuse resistant transmucosal drug delivery device
Apr, 2035

(11 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: NA

Dosage: FILM;BUCCAL

How can I launch a generic of BUNAVAIL before it's drug patent expiration?
More Information on Dosage

BUNAVAIL family patents

Family Patents

22. Calquence patents expiration

CALQUENCE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

US11771696 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 21, 2026

Drugs and Companies using ACALABRUTINIB ingredient

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocy...

Dosage: CAPSULE;ORAL

How can I launch a generic of CALQUENCE before it's drug patent expiration?
More Information on Dosage

CALQUENCE family patents

Family Patents

23. Calquence patents expiration

CALQUENCE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

US11771696 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 2021-10-31

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lympho...

Dosage: TABLET;ORAL

More Information on Dosage

CALQUENCE family patents

Family Patents

24. Cinvanti patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11744800 HERON THERAPS INC Methods of use of emulsion formulations of an NK-1 receptor antagonist
Sep, 2035

(11 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(11 years from now)

US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(11 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(11 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 09 November, 2017

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

How can I launch a generic of CINVANTI before it's drug patent expiration?
More Information on Dosage

CINVANTI family patents

Family Patents

25. Cyclophosphamide patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662342 EUGIA PHARMA SPECLTS Formulations of cyclophosphamide liquid concentrate
Jun, 2035

(11 years from now)

Drugs and Companies using CYCLOPHOSPHAMIDE ingredient

Market Authorisation Date: 25 August, 2021

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of CYCLOPHOSPHAMIDE before it's drug patent expiration?
More Information on Dosage

CYCLOPHOSPHAMIDE family patents

Family Patents

26. Cyclophosphamide patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849916 DR REDDYS Stable liquid formulations of cyclophosphamide and its impurities
Jul, 2035

(11 years from now)

US11382923 DR REDDYS Stable liquid formulations of cyclophosphamide and processes to prepare the same
Dec, 2035

(12 years from now)

Drugs and Companies using CYCLOPHOSPHAMIDE ingredient

Market Authorisation Date: 07 June, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of CYCLOPHOSPHAMIDE before it's drug patent expiration?
More Information on Dosage

CYCLOPHOSPHAMIDE family patents

Family Patents

27. Dayvigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188652 EISAI INC Compositions and methods for treating insomnia
Oct, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 7, 2025
M (M) Apr 20, 2026

Drugs and Companies using LEMBOREXANT ingredient

NCE-1 date: 2024-04-07

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

More Information on Dosage

DAYVIGO family patents

Family Patents

28. Definity patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10022460 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(12 years from now)

US11395856 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583207 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(12 years from now)

Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

DEFINITY family patents

Family Patents

29. Epidiolex patents expiration

EPIDIOLEX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11096905 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Oct, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9956185 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US9956184 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10709674 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10603288 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11633369 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10137095 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10111840 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US9956183 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10092525 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US9956186 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US9949937 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10709671 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11701330 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11357741 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11311498 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11446258 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11154516 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10709673 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10966939 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US10849860 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11766411 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(11 years from now)

US11400055 GW RES LTD Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(11 years from now)

US11065209 GW RES LTD Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(11 years from now)

US10918608 GW RES LTD Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2023
Orphan Drug Exclusivity (ODE) Jul 31, 2027
New Patient Population (NPP) Jul 31, 2023

Drugs and Companies using CANNABIDIOL ingredient

NCE-1 date: 2022-09-28

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of convulsive seizures in patients with dravet syndrome; Use in combination with clobazam for treatment of seizures in patients with lennox gastaut syndrome; Use for the treatmen...

Dosage: SOLUTION;ORAL

How can I launch a generic of EPIDIOLEX before it's drug patent expiration?
More Information on Dosage

EPIDIOLEX family patents

Family Patents

30. Ermeza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9345772 MYLAN Liquid levothyroxine formulations
Feb, 2035

(11 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 29 April, 2022

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage

ERMEZA family patents

Family Patents

31. Eskata patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098910 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(11 years from now)

US10729720 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(11 years from now)

US10493103 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(11 years from now)

US9980983 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(11 years from now)

US9675639 ACLARIS Peroxide formulations and methods and applicators for using the same
Jul, 2035

(11 years from now)

Drugs and Companies using HYDROGEN PEROXIDE ingredient

Market Authorisation Date: 14 December, 2017

Treatment: Treatment of seborrheic keratoses that are raised

Dosage: SOLUTION;TOPICAL

More Information on Dosage

ESKATA family patents

Family Patents

32. Evrysdi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 27, 2029
New Chemical Entity Exclusivity (NCE) Aug 7, 2025
New Patient Population (NPP) May 27, 2025
M (M) Oct 3, 2026

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 2024-08-07

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

EVRYSDI family patents

Family Patents

33. Evzio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone
Mar, 2035

(11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO family patents

Family Patents

34. Evzio (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone
Mar, 2035

(11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

35. Exem Foam Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259494 GISKIT Composition and method for medical imaging of body cavities
May, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 7, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: 2023-11-08

Market Authorisation Date: 07 November, 2019

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

More Information on Dosage

EXEM FOAM KIT family patents

Family Patents

36. Exkivity patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10227342 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(11 years from now)

US9796712 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 15, 2026
Orphan Drug Exclusivity (ODE) Sep 15, 2028

Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient

NCE-1 date: 2025-09-15

Market Authorisation Date: 15 September, 2021

Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...

Dosage: CAPSULE;ORAL

More Information on Dosage

EXKIVITY family patents

Family Patents

37. Fetroja patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10004750 SHIONOGI INC Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
Sep, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949982 SHIONOGI INC Preparation containing cephalosporin having a catechol moiety
Sep, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
New Indication (I) Sep 25, 2023
Generating Antibiotic Incentives Now (GAIN) Nov 14, 2029

Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient

NCE-1 date: 2028-11-14

Market Authorisation Date: 14 November, 2019

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

FETROJA family patents

Family Patents

38. Fintepla patents expiration

FINTEPLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10950331 ZOGENIX INC Control system for control of distribution of medication
Sep, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 25, 2029
New Product (NP) Jun 25, 2023
New Indication (I) Mar 25, 2025
Pediatric Exclusivity (PED) Sep 25, 2029

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution

Dosage: SOLUTION;ORAL

How can I launch a generic of FINTEPLA before it's drug patent expiration?
More Information on Dosage

FINTEPLA family patents

Family Patents

39. Firvanq Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959948 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(11 years from now)

US11638692 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(11 years from now)

US10959947 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(11 years from now)

US10959949 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(11 years from now)

US10959946 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(11 years from now)

US10688046 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(11 years from now)

US10493028 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(11 years from now)

Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient

Market Authorisation Date: 26 January, 2018

Treatment: Treatment of staphylococcal enterocolitis; Treatment of c. difficile-associated diarrhea

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of FIRVANQ KIT before it's drug patent expiration?
More Information on Dosage

FIRVANQ KIT family patents

Family Patents

40. Genosyl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10737051 VERO BIOTECH Nitrogen dioxide storage device
Oct, 2035

(11 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: NA

Dosage: GAS;INHALATION

More Information on Dosage

GENOSYL family patents

Family Patents

41. Hetlioz patents expiration

HETLIOZ Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11760740 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(11 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(11 years from now)

US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(11 years from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(11 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Dec 1, 2023
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration...

Dosage: CAPSULE;ORAL

How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage

HETLIOZ family patents

Family Patents

42. Hetlioz Lq patents expiration

HETLIOZ LQ Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(11 years from now)

US11760740 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(11 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(11 years from now)

US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(11 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Dec 1, 2023
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by admi...

Dosage: SUSPENSION;ORAL

More Information on Dosage

HETLIOZ LQ family patents

Family Patents

43. Illuccix patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027031 TELIX Kit for radiolabelling
Jul, 2035

(11 years from now)

Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Market Authorisation Date: 17 December, 2021

Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ILLUCCIX family patents

Family Patents

44. Imbruvica patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9795604

(Pediatric)

PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Apr, 2035

(11 years from now)

US10463668

(Pediatric)

PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Apr, 2035

(11 years from now)

US10695350

(Pediatric)

PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Apr, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 24, 2029
ODE* (ODE*) Aug 2, 2024
New Patient Population (NPP) Aug 24, 2025
Pediatric Exclusivity (PED) Feb 24, 2026

Drugs and Companies using IBRUTINIB ingredient

Market Authorisation Date: 16 February, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents

45. Impoyz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855334 PRIMUS PHARMS Topical compositions comprising a corticosteroid
Mar, 2035

(11 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: NA

Dosage: CREAM;TOPICAL

How can I launch a generic of IMPOYZ before it's drug patent expiration?
More Information on Dosage

IMPOYZ family patents

Family Patents

46. Inlyta patents expiration

INLYTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Feb, 2035

(11 years from now)

Drugs and Companies using AXITINIB ingredient

Market Authorisation Date: 27 January, 2012

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage

INLYTA family patents

Family Patents

47. Isturisa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143680 RECORDATI RARE Pharmaceutical dosage forms
Jul, 2035

(11 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms
Oct, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2025
Orphan Drug Exclusivity (ODE) Mar 6, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: 2024-03-06

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage

ISTURISA family patents

Family Patents

48. Jublia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478601 BAUSCH Applicator
Apr, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Apr 27, 2023

Drugs and Companies using EFINACONAZOLE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient

Dosage: SOLUTION;TOPICAL

How can I launch a generic of JUBLIA before it's drug patent expiration?
More Information on Dosage

JUBLIA family patents

Family Patents

49. Jylamvo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129833 THERAKIND Methotrexate formulation
Oct, 2035

(11 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 29 November, 2022

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage

JYLAMVO family patents

Family Patents

50. Kapspargo Sprinkle patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504655 SPIL Capsule dosage form of metoprolol succinate
Jul, 2035

(11 years from now)

US9700530 SPIL Capsule dosage form of metoprolol succinate
Jul, 2035

(11 years from now)

Drugs and Companies using METOPROLOL SUCCINATE ingredient

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

KAPSPARGO SPRINKLE family patents

Family Patents

51. Kengreal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295687 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(11 years from now)

US10039780 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(11 years from now)

US9439921 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(11 years from now)

US9700575 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(11 years from now)

Drugs and Companies using CANGRELOR ingredient

Market Authorisation Date: 22 June, 2015

Treatment: Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous inf...

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of KENGREAL before it's drug patent expiration?
More Information on Dosage

KENGREAL family patents

Family Patents

52. Kimyrsa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 12, 2024
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 2023-08-07

Market Authorisation Date: 12 March, 2021

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

KIMYRSA family patents

Family Patents

53. Lenvima patents expiration

LENVIMA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10407393 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(11 years from now)

US11186547 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(11 years from now)

US10259791 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 15, 2025
M (M) Dec 19, 2024
New Indication (I) Aug 10, 2024

Drugs and Companies using LENVATINIB MESYLATE ingredient

Market Authorisation Date: 13 February, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage

LENVIMA family patents

Family Patents

54. Licart patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11351133 IBSA INST BIO Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug
Feb, 2035

(11 years from now)

US11344520 IBSA INST BIO Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug
Feb, 2035

(11 years from now)

Drugs and Companies using DICLOFENAC EPOLAMINE ingredient

Market Authorisation Date: 19 December, 2018

Treatment: Method of treating acute pain due to minor strains, sprains, and contusions using a diclofenac patch containing heparin for once daily administration where heparin is not released

Dosage: SYSTEM;TOPICAL

More Information on Dosage

LICART family patents

Family Patents

55. Lodoco patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10265281 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Jan, 2035

(11 years from now)

US10842762 AGEPHA PHARMA FZ Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Jan, 2035

(11 years from now)

US11026899 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Jan, 2035

(11 years from now)

US11026900 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Jan, 2035

(11 years from now)

US9744144 AGEPHA PHARMA FZ Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Jan, 2035

(11 years from now)

US10206891 AGEPHA PHARMA FZ Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Jan, 2035

(11 years from now)

US11026901 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Jan, 2035

(11 years from now)

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 16 June, 2023

Treatment: A method for treating and/or reducing the risk of a cardiovascular event; A method of treating and/or reducing the risk of inflammation, atherosclerotic vascular disease, and cholesterol crystal induc...

Dosage: TABLET;ORAL

More Information on Dosage

LODOCO family patents

Family Patents

56. Lokelma patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9592253 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(11 years from now)

US10300087 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11738044 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 18, 2023
M (M) Apr 24, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: 2022-05-18

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of LOKELMA before it's drug patent expiration?
More Information on Dosage

LOKELMA family patents

Family Patents

57. Lonhala Magnair Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376661 SUNOVION RESP Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element
Sep, 2035

(11 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage

LONHALA MAGNAIR KIT family patents

Family Patents

58. Mavyret patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE48923 ABBVIE INC Crystal forms
May, 2035

(11 years from now)

US9321807 ABBVIE INC Crystal forms
Jun, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48923

(Pediatric)

ABBVIE INC Crystal forms
Nov, 2035

(11 years from now)

US9321807

(Pediatric)

ABBVIE INC Crystal forms
Dec, 2035

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Apr 10, 2023
Orphan Drug Exclusivity (ODE) Jun 10, 2028
Pediatric Exclusivity (PED) Dec 10, 2028

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: NA

Dosage: PELLETS;ORAL

More Information on Dosage

MAVYRET family patents

Family Patents

59. Narcan patents expiration

NARCAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211253 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(11 years from now)

US10085937 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(11 years from now)

US9561177 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(11 years from now)

US9629965 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(11 years from now)

US9468747 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(11 years from now)

US9707226 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(11 years from now)

US9775838 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(11 years from now)

US9480644 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 November, 2015

Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of NARCAN before it's drug patent expiration?
More Information on Dosage

NARCAN family patents

Family Patents

60. Nityr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10328029 CYCLE PHARMS LTD Pharmaceutical composition
Jan, 2035

(11 years from now)

Drugs and Companies using NITISINONE ingredient

Market Authorisation Date: 26 July, 2017

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Dosage: TABLET;ORAL

More Information on Dosage

NITYR family patents

Family Patents

61. Obredon patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10105324 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(11 years from now)

US9549907 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(11 years from now)

US9808431 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(11 years from now)

Drugs and Companies using GUAIFENESIN; HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 14 November, 2014

Treatment: A method of increasing the bioavailability of guaifenesin in a solution containing 54% to 66% by weight of propylene glycol and glycerol, wherein the method increases the cmax by at least 1.5 and/or i...

Dosage: SOLUTION;ORAL

More Information on Dosage

OBREDON family patents

Family Patents

62. Ojjaara patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE48285 GLAXOSMITHKLINE N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
Jun, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9809559 GLAXOSMITHKLINE (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
Jun, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 15, 2030
New Chemical Entity Exclusivity (NCE) Sep 15, 2028

Drugs and Companies using MOMELOTINIB DIHYDROCHLORIDE ingredient

NCE-1 date: 2027-09-16

Market Authorisation Date: 15 September, 2023

Treatment: For the treatment of intermediate or high-risk myelofibrosis

Dosage: TABLET;ORAL

More Information on Dosage

OJJAARA family patents

Family Patents

63. Omlonti patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10774072 SANTEN Crystal of N-substituted sulfonamide compound
Jun, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415038 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US11197849 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US10179127 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US10765750 SANTEN Pharmaceutical composition containing pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

USRE48183 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US10702511 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: 2026-09-22

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

OMLONTI family patents

Family Patents

64. Ongentys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357468 NEUROCRINE Medicaments for slowing Parkinson's disease
May, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: 2024-04-24

Market Authorisation Date: 24 April, 2020

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease

Dosage: CAPSULE;ORAL

More Information on Dosage

ONGENTYS family patents

Family Patents

65. Onpattro patents expiration

Can you believe ONPATTRO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11079379 ALNYLAM PHARMS INC Methods of treating transthyretin (TTR) mediated amyloidosis
Aug, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 10, 2025
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

Drugs and Companies using PATISIRAN SODIUM ingredient

NCE-1 date: 2022-08-10

Market Authorisation Date: 10 August, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ONPATTRO family patents

Family Patents

66. Opfolda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10208299 AMICUS THERAP US Highly potent acid alpha-glucosidase with enhanced carbohydrates
Sep, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10961522 AMICUS THERAP US Highly potent acid alpha-glucosidase with enhanced carbohydrates
Sep, 2035

(11 years from now)

US11753632 AMICUS THERAP US Highly potent acid alpha-glucosidase with enhanced carbohydrates
Sep, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Sep 28, 2026

Drugs and Companies using MIGLUSTAT ingredient

Market Authorisation Date: 28 September, 2023

Treatment: The treatment of pompe patients

Dosage: CAPSULE;ORAL

More Information on Dosage

OPFOLDA family patents

Family Patents

67. Orbactiv patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 2023-08-07

Market Authorisation Date: 06 August, 2014

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ORBACTIV family patents

Family Patents

68. Orladeyo patents expiration

Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10329260 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(11 years from now)

US10125102 BIOCRYST Human plasma kallikrein inhibitors
Apr, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10689346 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(11 years from now)

US11230530 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(11 years from now)

US11708333 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 3, 2027
New Chemical Entity Exclusivity (NCE) Dec 3, 2025

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: 2024-12-03

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and ped...

Dosage: CAPSULE;ORAL

More Information on Dosage

ORLADEYO family patents

Family Patents

69. Otiprio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9220796 ALK ABELLO Sterilization of ciprofloxacin composition
Jul, 2035

(11 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 10 December, 2015

Treatment: NA

Dosage: INJECTABLE, SUSPENSION;OTIC

More Information on Dosage

OTIPRIO family patents

Family Patents

70. Oxbryta patents expiration

OXBRYTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9447071 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722502 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(11 years from now)

US11452720 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 25, 2024
Orphan Drug Exclusivity (ODE) Dec 17, 2028

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 2023-11-26

Market Authorisation Date: 17 December, 2021

Treatment: Treating sickle cell disease by administering voxelotor and another active agent

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage

OXBRYTA family patents

Family Patents

71. Oxlumo patents expiration

Can you believe OXLUMO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

US10612027 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

US11446380 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Oct, 2035

(11 years from now)

US10478500 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
Oct, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 6, 2029
New Chemical Entity Exclusivity (NCE) Nov 23, 2025
New Indication (I) Oct 6, 2025

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: 2024-11-23

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

OXLUMO family patents

Family Patents

72. Pemazyre patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9611267 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jan, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
Orphan Drug Exclusivity (ODE) Aug 26, 2029
New Indication (I) Aug 26, 2025

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

PEMAZYRE family patents

Family Patents

73. Pemetrexed patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11147817 SHILPA Pharmaceutical composition of pemetrexed
Mar, 2035

(11 years from now)

Drugs and Companies using PEMETREXED DISODIUM ingredient

Market Authorisation Date: 22 May, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PEMETREXED family patents

Family Patents

74. Pemfexy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9604990 EAGLE PHARMS Crystalline forms of pemetrexed diacid and manufacturing processes therefor
Oct, 2035

(11 years from now)

Drugs and Companies using PEMETREXED ingredient

Market Authorisation Date: 08 February, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PEMFEXY family patents

Family Patents

75. Ponvory patents expiration

PONVORY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220023 JANSSEN PHARMS Dosing regimen for a selective S1P1 receptor agonist
Dec, 2035

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 2025-03-18

Market Authorisation Date: 18 March, 2021

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titratio...

Dosage: TABLET;ORAL

More Information on Dosage

PONVORY family patents

Family Patents

76. Proair Digihaler patents expiration

PROAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782551 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(11 years from now)

US9782550 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(11 years from now)

US10918816 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(12 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

PROAIR DIGIHALER family patents

Family Patents

77. Qalsody patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10385341 BIOGEN MA Compositions for modulating SOD-1 expression
Apr, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10669546 BIOGEN MA Compositions for modulating SOD-1 expression
Apr, 2035

(11 years from now)

US10968453 BIOGEN MA Compositions for modulating SOD-1 expression
Apr, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 25, 2030
New Chemical Entity Exclusivity (NCE) Apr 25, 2028

Drugs and Companies using TOFERSEN ingredient

NCE-1 date: 2027-04-26

Market Authorisation Date: 25 April, 2023

Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults who have a mutation in the superoxide dismutase 1 (sod1) gene

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage

QALSODY family patents

Family Patents

78. Qbrelis patents expiration

QBRELIS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9814751 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US11771733 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10940177 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US11179434 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9463183 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10265370 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10406199 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10039800 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9616096 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

Drugs and Companies using LISINOPRIL ingredient

Market Authorisation Date: 29 July, 2016

Treatment: Treatment of myocardial infarction; Method of treating hypertension; Treatment of heart failure; Method of treatment of heart failure; Reduction of mortality in acute myocardial infarction; Treatment ...

Dosage: SOLUTION;ORAL

How can I launch a generic of QBRELIS before it's drug patent expiration?
More Information on Dosage

QBRELIS family patents

Family Patents

79. Qulipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836 ABBVIE INC Tablet formulation for CGRP active compounds
Jan, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Apr 17, 2026
New Chemical Entity Exclusivity (NCE) Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: 2025-09-28

Market Authorisation Date: 28 September, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

QULIPTA family patents

Family Patents

80. Rezlidhia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9834539 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10550098 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(11 years from now)

US10414752 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(11 years from now)

US11498913 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 1, 2027
Orphan Drug Exclusivity (ODE) Dec 1, 2029

Drugs and Companies using OLUTASIDENIB ingredient

NCE-1 date: 2026-12-01

Market Authorisation Date: 01 December, 2022

Treatment: A method of treating a cancer where the cancer is acute myeloid leukemia (aml)

Dosage: CAPSULE;ORAL

More Information on Dosage

REZLIDHIA family patents

Family Patents

81. Rezurock patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311541 KADMON PHARMS LLC Treatment of GVHD
Apr, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 16, 2026
Orphan Drug Exclusivity (ODE) Jul 16, 2028

Drugs and Companies using BELUMOSUDIL MESYLATE ingredient

NCE-1 date: 2025-07-16

Market Authorisation Date: 16 July, 2021

Treatment: Treatment of adults and pediatric patients 12 and older with sclerodermatous form of chronic graft-versus-host disease ( cgvhd) after failure of at least two prior lines of systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage

REZUROCK family patents

Family Patents

82. Rhofade patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11517560 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(11 years from now)

US10335391 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(11 years from now)

US10751325 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(11 years from now)

US9974773 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(11 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 January, 2017

Treatment: Once daily topical treatment of persistent facial erythema associated with rosacea in female adults; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1...

Dosage: CREAM;TOPICAL

How can I launch a generic of RHOFADE before it's drug patent expiration?